&w=3840&q=100)
Sterling & Wilson Renewable Energy up 2% on emerging lowest bidder; details
Sterling & Wilson Renewable Energy share price: Sterling & Wilson Renewable Energy Limited (SWREL) shares were buzzing in trade on Thursday, May 29, 2025, with the stock rising as much as 2.33 per cent to an intraday high of ₹288.90 per share.
At 1:47 PM, Sterling & Wilson Renewable Energy shares continued to trade near day's high level, up 1.66 per cent at ₹287 apiece. In comparison, BSE Sensex was trading flat with a positive bias at 81,345.43 levels.
Why did Sterling & Wilson Renewable Energy share rise?
Sterling and Wilson Renewable Energy rose after it announced that the company has emerged as L1 bidder (lowest bidder) for a turn-key EPC package for development of a 225 MW (AC) grid connected solar PV project in Gujarat, India.
In a press statement, the company said, 'Sterling and Wilson Renewable Energy Limited (SWREL), a leading domestic renewable EPC is proud to announce that the company has emerged as L1 bidder in a tender of a leading PSU developer for a turn-key EPC package for development of a 225 MW (AC) grid connected Solar PV Project in Gujarat, India.'
On securing the deal, Chandra Kishore Thakur, global CEO of Sterling and Wilson Renewable Energy Group, said, 'We are thrilled to announce our first domestic order of FY26 from a very reputed PSU developer and continue to build on our strong position in the Gujarat market. Our domestic pipeline remains very robust and we are confident of building on this order win.'
About Sterling & Wilson Renewable Energy
Sterling and Wilson Renewable Energy Limited (SWREL) is a global, pure-play provider of end-to-end renewable energy engineering, procurement, and construction (EPC) solutions.
The company engages in utility-scale solar, floating solar, and hybrid energy storage projects, with a total portfolio exceeding 22.6 GWp, including both commissioned projects and those under construction.
Sterling & Wilson Renewable Energy also operates and maintains 8.7 GWp of solar assets, including projects built by third parties.
With a presence in 28 countries, the company operates across India, Southeast Asia, the Middle East, Africa, Europe, Australia, and the Americas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
8 minutes ago
- Business Standard
Talbros Automotive share jumps 8% on securing this deal; key details here
Talbros Automotive share price: Talbros Automotive share price was in demand on Wednesday, June 11, 2025, with the scrip rallying up to 8.26 per cent to hit an intraday high of ₹322.85 per share. At 1:46 PM, Talbros Automotive shares were trading 2.23 per cent higher at ₹304.85 per share. In comparison, BSE Sensex was trading 0.18 per cent higher at 82,542.49 levels. What triggered the rally in Talbros Automotive share price today? Talbros Automotive share price surged today after the company, along with its joint ventures, secured orders worth approximately ₹580 crore from leading OEMs for both domestic and export markets. These orders will be executed over the next five (5) years. The fresh orders span across all major product lines—gaskets, heat shields, forging components, chassis systems, and hoses. The company's sealing business alone bagged orders worth ₹260 crore, including around Rs 150 crore from exports—primarily to Europe. This includes ₹180 crore in gasket and heat shield products from multiple OEMs, and ₹80 crore for the forgings division. 'By strategically increasing its exports to Europe—a region known for its stringent quality standards and specialisation in the automotive components industry—the company is deepening its footprint in a highly competitive and demanding market. This expansion not only demonstrates the company's capability to meet global benchmarks but also positions it as a reliable supplier within the European automotive ecosystem. As a result, the company is gaining market share in this region,' said Talbros Automotive, in a statement. ALSO READ | In addition, its JV with Marelli Talbros Chassis Systems received orders worth ₹290 crore for chassis components, with nearly half (about 50 per cent) catering to the electric vehicle (EV) segment. Another JV, Talbros Marugo Rubber, won ₹30 crore in orders for hoses and anti-vibration parts in the domestic market, with commercialisation expected in the second half of the financial year 2026 (H2FY26). 'These orders will help further enhance the company's revenue visibility and improve profitability,' Talbros Automotive added. About Talbros Automotive Founded in 1956, Talbros Automotive Components is the flagship manufacturing arm of the Talbros Group. The company began its journey with the production of automotive and industrial gaskets in collaboration with Coopers Payen of the UK. Talbros, along with its joint venture partners, operates 10 state-of-the-art manufacturing facilities across Haryana, Uttarakhand, and Maharashtra, supported by a dedicated R&D centre in Faridabad. The company caters to a prestigious clientele including Bajaj Auto, Tata Cummins, Ashok Leyland, Maruti Suzuki, Honda, John Deere, and Mahindra & Mahindra, among others. It also has a strong presence in the aftermarket and holds a Mercedes-Benz dealership under the Talbros Group umbrella.
The Print
16 minutes ago
- The Print
Rupee settles 9 paise higher at 85.57 against US dollar
Foreign institutional investors (FIIs) purchased equities worth Rs 2,301.87 crore on a net basis on Tuesday, according to exchange data. However, a mixed sentiment in the domestic equity markets, a rise in global crude oil prices, and a stronger US dollar against major currencies capped further gains in the local unit, according to forex traders. Mumbai, Jun 10 (PTI) The Indian rupee rose 9 paise to close at 85.57 against the US dollar on the back of strong foreign capital inflows. At the interbank foreign exchange, rupee opened at 85.62 and registered an intra-day peak of 85.51 and a low of 85.68 before settling at 85.57 against the greenback, up 9 paise from its previous close. The local unit had settled at 85.66 against the US dollar on Monday. 'The USD-INR spot pair has been consolidating within a tight range of 85.00 to 86.00, with market participants awaiting a decisive trigger. Comfortable liquidity conditions in the money market, following the cash reserve ratio (CRR) reduction, have led to a softening in forward premiums as interest rate differentials between India and the US continue to narrow. This has made forward hedging less attractive for exporters,' Anindya Banerjee, Head Currency & Commodity, Kotak Securities, said. 'We expect the RBI to stay active in the forex market to curb excessive volatility. On the domestic front, India's relatively stable macroeconomic fundamentals continue to provide a firm underpinning to the rupee,' he said. In the domestic equity market, the 30-share BSE Sensex declined 53.49 points to settle at 82,391.72, while the Nifty edged up to close at 25,104.25. Meanwhile, the dollar index, which gauges the greenback's strength against a basket of six currencies, was trading higher by 0.15 per cent at 99.09. 'The next significant directional cue for the pair is likely to emerge from risk sentiment and the broader trend in the US Dollar Index (DXY), which is currently attempting to establish a short-term base. A sustained move above the 100.00 mark in the DXY could propel USD-INR beyond the 86.00 resistance, with a potential extension towards 86.50,' Banerjee said. Brent crude, the global oil benchmark, rose 0.18 per cent to USD 67.16 per barrel in futures trade. According to Anuj Choudhary – Research Analyst at Mirae Asset Sharekhan, 'Optimism over talks between US and China led to rise in risk appetite in global markets. However, a positive US dollar and rising crude oil prices capped sharp gains. 'Investors may watch out for CPI data from the US this week. USD-INR spot price is expected to trade in a range of Rs 85.35 to Rs 86,' he added. PTI TRB HVA This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Rekha Jhunjhunwala portfolio stock soars 17%; zooms over 950% in 2 years
Wockhardt share price today: Shares of pharmaceutical company Wockhardt hit an all-time high of ₹1,809.95, as they rallied 17 per cent on the BSE in Wednesday's intra-day trade amid heavy volumes on healthy business outlook. The stock price of this smallcap pharmaceutical company surpassed its previous high of ₹1,678.60, which it had touched on February 6, 2025. In the past one month, Wockhardt has outperformed the market by surging 47 per cent, as compared to 0.3 per cent rise in the BSE Sensex. Further, in the past year, the stock zoomed 206 per cent, as against 8 per cent gain in the benchmark index. The stock price of Wockhardt has skyrocketed 956 per cent from level of ₹171.45 on the BSE. At 12:36 PM; the stock was quoting 16 per cent higher at ₹1,802.40, as against 0.33 per cent gain in the BSE Sensex. The average trading volumes on the counter jumped three-fold. A combined 4.34 million shares have changed hands on the NSE and BSE. Rekha Jhunjhunwala held over 1 per cent holding in Wockhardt Ace investor Rekha Jhunjhunwala held 2.84 million shares representing 1.75 per cent stake in Wockhardt at the end of March 31, 2025, the shareholding pattern data shows. Strong FY25 results Wockhardt had reported a strong operational performance with 67 per cent year-on-year (Y-o-Y) growth in earnings before interest, taxes, depreciation, and amortisation (Ebitda) at ₹418 crore for the financial year 2024-25 (FY25) compared to ₹251 crore in the previous year (FY24). Ebitda margin improved to 13.8 per cent, from 8.7 per cent. Revenue, however, grew 5 per cent Y-o-Y to ₹3,033 crore in FY25, compared to ₹2,879 crore in FY24. For FY25, the company said its net loss stood at ₹57 crore as compared to ₹472 crore in the year-ago period. Zaynich: Planned for filing in USA by August 2025 Following the completion of the Global, pivotal, registration-enabling, Phase III study in hospitalised complicated urinary tract infection (cUTI) patients, Wockhardt's Zaynich has demonstrated the highest-ever efficacy achieving a clinical cure rate of 96.8 per cent. Wockhardt, while announcing Q4 results on May 29, 2025, said that this study is NDA-enabling, based on which marketing authorisation applications will be made to global health authorities including India, US, EMA and MHRA. For India, the Drug Controller General of India (DCGI) filing for commercial approval was submitted on March 31, 2025. In parallel, preparations for the US New Drug Application (NDA) filings are progressing, marked by the successful completion of a pre-NDA meeting with the US Food and Drug Administration (FDA). Filing in the USA is expected by August 2025, the company said. Meanwhile, Wockhardt, which is all set to launch its new class of antibiotic Zaynich targeted at treating complicated gram-negative infections in India this year, estimates that the drug would have an addressable market of $7 billion in the US and Europe, besides a ₹17,000 crore opportunity in India, taking the total opportunity to $9 billion. The company is expecting to get a nod from the DCGI soon. It hopes for a launch in the second half of this financial year. In an investor presentation, Wockhardt said that it had completed the pre-ANDA meeting with the US Food and Drug Administration (USFDA) in May and is filing with the regulator in Q2FY26, expecting a potential launch in the financial year 2026-27 (FY27). It aims to file for approval in the European Union (EU) and emerging markets in H2FY26. Apart from Zaynich, Wockhardt is pinning its hopes on other drugs in its antibiotic portfolio (like Miqnaf or Nafithromycin), and its biotechnology portfolio including insulins. Miqnaf is targeting a ₹10,800 crore market opportunity in India with over 96 million potential prescriptions. About Wockhardt Wockhardt is a research based Global Pharmaceutical and Biotech company. Wockhardt's New Drug Discovery programme has focussed on the unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of its Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'. It has a comprehensive Drug Discovery team and clinical organisation. Wockhardt has a significant presence in the USA, Europe and India, with 77 per cent of its global revenues coming from international businesses.
